Pacific Biosciences of California Future Growth

Future criteria checks 2/6

Pacific Biosciences of California is forecast to grow earnings and revenue by 20.5% and 20.8% per annum respectively. EPS is expected to grow by 23.7% per annum. Return on equity is forecast to be -32.7% in 3 years.

Key information

20.5%

Earnings growth rate

23.7%

EPS growth rate

Life Sciences earnings growth	15.9%
Revenue growth rate	20.8%
Future return on equity	-32.7%
Analyst coverage	Good
Last updated	18 Apr 2024

Recent future growth updates

Recent updates

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Apr 16

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Mar 19

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Feb 08

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Feb 01

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Dec 18

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

Nov 13

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Aug 28

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Jul 31

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Jul 06

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

May 25

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Mar 29

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Feb 26

Time To Worry? Analysts Just Downgraded Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Outlook

Aug 08

Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio

Jul 27

Is Pacific Biosciences of California (NASDAQ:PACB) Using Debt Sensibly?

Jul 11

Pacific Biosciences Hit By Sentiment, But The Future Of Long-Read Sequencing Is Strong

Apr 05

Is Pacific Biosciences of California (NASDAQ:PACB) Using Too Much Debt?

Feb 24

Earnings and Revenue Growth Forecasts

NasdaqGS:PACB - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	377	-176	-82	-80	10
12/31/2025	294	-234	-178	-144	12
12/31/2024	194	-281	-230	-185	8
12/31/2023	201	-307	-268	-259	N/A
9/30/2023	170	-309	-274	-262	N/A
6/30/2023	146	-319	-275	-260	N/A
3/31/2023	134	-321	-296	-279	N/A
12/31/2022	128	-314	-280	-263	N/A
9/30/2022	137	-299	-249	-234	N/A
6/30/2022	140	-206	-224	-212	N/A
3/31/2022	135	-175	-176	-167	N/A
12/31/2021	131	-181	-117	-111	N/A
9/30/2021	122	-37	-97	-94	N/A
6/30/2021	106	-77	-73	-71	N/A
3/31/2021	92	-59	-80	-79	N/A
12/31/2020	79	29	18	20	N/A
9/30/2020	80	-46	14	16	N/A
6/30/2020	83	-51	15	16	N/A
3/31/2020	90	-53	21	22	N/A
12/31/2019	91	-84	-81	-78	N/A
9/30/2019	82	-115	-82	-79	N/A
6/30/2019	79	-111	-78	-76	N/A
3/31/2019	76	-109	-76	-73	N/A
12/31/2018	79	-103	-68	-66	N/A
9/30/2018	84	-93	-71	-68	N/A
6/30/2018	89	-90	-77	-71	N/A
3/31/2018	88	-93	-78	-70	N/A
12/31/2017	93	-92	-78	-68	N/A
9/30/2017	94	-90	N/A	-60	N/A
6/30/2017	96	-86	N/A	-58	N/A
3/31/2017	97	-79	N/A	-64	N/A
12/31/2016	91	-74	N/A	-68	N/A
9/30/2016	101	-57	N/A	-56	N/A
6/30/2016	90	-37	N/A	-56	N/A
3/31/2016	94	-31	N/A	-44	N/A
12/31/2015	93	-32	N/A	-48	N/A
9/30/2015	73	-49	N/A	-63	N/A
6/30/2015	80	-60	N/A	-53	N/A
3/31/2015	67	-67	N/A	-59	N/A
12/31/2014	61	-66	N/A	-51	N/A
9/30/2014	53	-64	N/A	-51	N/A
6/30/2014	40	-76	N/A	-26	N/A
3/31/2014	34	-77	N/A	-29	N/A
12/31/2013	28	-79	N/A	-30	N/A
9/30/2013	25	-84	N/A	-33	N/A
6/30/2013	20	-86	N/A	-70	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PACB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PACB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PACB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PACB's revenue (20.8% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: PACB's revenue (20.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PACB is forecast to be unprofitable in 3 years.

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Pacific Biosciences of California Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 16% to US$8.44

Consensus revenue estimates decrease by 11%, EPS upgraded

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

Price target decreased by 11% to US$9.41

Price target decreased by 9.2% to US$11.17

Price target decreased by 7.7% to US$11.92

Recent updates

New major risk - Share price stability

Price target decreased by 16% to US$8.44

Consensus revenue estimates decrease by 11%, EPS upgraded

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Price target decreased by 11% to US$9.41

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions

Insider recently bought US$176k worth of stock

Full year 2023 earnings: EPS misses analyst expectations

President recently sold US$481k worth of stock

President notifies of intention to sell stock

Price target decreased by 9.2% to US$11.17

Full year 2023 earnings: EPS misses analyst expectations

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Pacific Biosciences of California, Inc Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Pacific Biosciences of California, Inc. to Report Q4, 2023 Results on Feb 15, 2024

PacBio Announces New Nanobind Pandna Kit Enabling Hifi Optimized Dna Extraction Solutions

Chief Operating Officer recently sold US$241k worth of stock

Price target decreased by 7.7% to US$11.92

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Pacific Biosciences of California, Inc. Announces Resignation of David Botstein from the Board

Price target decreased by 7.3% to US$12.67

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pacific Biosciences of California, Inc. Appoints David Meline to Audit Committee

Price target decreased by 10% to US$13.92

Pacific Biosciences of California, Inc. Appoints David Meline to its Board of Directors

Pacific Biosciences of California, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Pacbio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

President recently sold US$980k worth of stock

President notifies of intention to sell stock

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Chief Operating Officer recently sold US$287k worth of stock

Chief Operating Officer notifies of intention to sell stock

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for approximately $110 million.

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pacific Biosciences of California, Inc. (NasdaqGS:PACB) entered into an agreement to acquire Apton Biosystems, Inc. for $110 million.

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Pacific Biosciences of California, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Price target increased by 8.6% to US$14.73

Now 20% undervalued

Pacific Biosciences of California, Inc. Announces Board Changes

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

Now 24% undervalued

VP & Chief Accounting Officer recently sold US$65k worth of stock

Price target increased by 9.1% to US$13.50

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Independent Director notifies of intention to sell stock

President notifies of intention to sell stock

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Full year 2022 earnings: EPS misses analyst expectations

PacBio to Expand MAS-Seq Technology to 16S rRNA and Bulk RNA-Seq Solutions

Pacific Biosciences of California, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Insufficient new directors

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. has completed a Follow-on Equity Offering in the amount of $175 million.

Pacific Biosciences of California, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2022

Pacific Biosciences of California, Inc. Announces Board Appointments

Pacific Biosciences of California, Inc. Withdraws its Financial Guidance

Pacific Biosciences of California, Inc. to Report Q3, 2022 Results on Nov 07, 2022

PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery

PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing

Chief Financial Officer recently sold US$73k worth of stock